Dihexa — Background and Chemical Identity

• Chemical name / synonyms: Dihexa; N‑hexanoic‑Tyr‑Ile‑(6)‑aminohexanoic amide; PNB‑0408. Wikipedia+2ChemicalBook+2
• CAS number: 1401708‑83‑5. Wikipedia+1
• Molecular formula & structure: C₍₂₇₎H₍₄₄₎N₄O₅ — oligopeptide with molecular weight ≈ 504.66 Dalton. ChemicalBook+1
• Mechanism of action: Dihexa is derived from Angiotensin IV (Ang IV) and acts as a potent mimetic of Hepatocyte Growth Factor (HGF), binding with high affinity to HGF and potentiating its activity at the c-Met receptor. This triggers downstream signaling pathways that promote synaptogenesis (formation of new synapses), spinogenesis (dendritic spine formation), and neuroplasticity. PubMed Central+2Wikipedia+2
• Blood–brain barrier (BBB) permeability and bioavailability: Unlike many neurotrophic peptides, Dihexa is reported to cross the blood–brain barrier and remain metabolically stable — rendering it a candidate for central nervous system (CNS) effects. ScienceDirect+2ChemicalBook+2

Preclinical Evidence: Neuroprotective, Synaptogenic, Cognitive Effects

• In neuronal‑cell culture, Dihexa (and an Ang IV analog) induced hippocampal spinogenesis and synaptogenesis comparable to HGF itself — effects that were blocked when HGF/c‑Met signaling was inhibited. PubMed Central+1
• In aged or chemically impaired (e.g. scopolamine) rodent models of cognitive deficit, Dihexa administration improved memory and learning performance (e.g. on spatial memory tasks), suggesting “procognitive” and antidementia potential. ScienceDirect+2Genetic Engineering & Biotechnology News+2
• In a model of Alzheimer‑like disease in transgenic mice (APP/PS1 mice), recent preclinical work reported that Dihexa (orally administered) rescued cognitive impairment, improved spatial learning in the Morris water maze, increased neuronal cell counts and synaptic protein (SYP) expression, reduced neuroinflammation (lowered pro‑inflammatory cytokines, increased anti‑inflammatory markers), and activated the PI3K/AKT signaling pathway — a pathway implicated in cell survival and neuroprotection. ResearchGate+2ResearchGate+2
• A systematic review of studies on Ang IV and its analogs (including Dihexa) found that in models of cognitive impairment, a majority demonstrated improved spatial working memory and passive avoidance — further supporting procognitive potential of Ang‑IV analogs such as Dihexa. PubMed Central+1

Because of these effects, Dihexa has been proposed as a neuroregenerative/neuroprotective agent — with potential relevance for memory disorders, neurodegenerative diseases (e.g. Alzheimer’s, Parkinson’s), traumatic brain injury, or age‑related cognitive decline. Evolution Integrative Medicine+2Michael J. Fox Foundation+2

Proposed/Potential Benefits (Based on Preclinical Data)

• Enhanced synaptogenesis / neuroplasticity — Dihexa promotes formation of new synapses and dendritic spines, potentially enabling structural brain remodeling. PubMed Central+2ScienceDirect+2
• Improved memory and learning — In animal models of cognitive impairment or aging, Dihexa improved performance on memory/learning tasks, indicating improved cognitive function. Genetic Engineering & Biotechnology News+2PubMed Central+2
• Neuroprotection and neuroregeneration potential — By activating HGF/c‑Met signaling — a pathway involved in neuronal survival, growth, and repair — Dihexa may help in recovery from neurodegenerative insults, injury, or degeneration. PubMed Central+2Michael J. Fox Foundation+2
• Oral bioavailability and BBB permeability — Unlike many growth‑factor molecules, Dihexa is small and stable enough to cross the blood–brain barrier and be delivered systemically (e.g. orally or via systemic dosing), improving its theoretical therapeutic feasibility. ChemicalBook+2Genetic Engineering & Biotechnology News+2
• Potential to treat neurodegenerative diseases or cognitive decline — Given the preclinical evidence, Dihexa has been suggested as candidate for treatment or mitigation of diseases such as Alzheimer’s, Parkinson’s, and perhaps cognitive deficits due to aging or brain injury. Michael J. Fox Foundation+2Genetic Engineering & Biotechnology News+2

Known Risks, Limitations, and Key Concerns

• Lack of robust human clinical data: The publicly available literature on Dihexa is almost entirely preclinical (animal and cell studies). As of now, there is no widely published, peer‑reviewed human clinical trial demonstrating safety, efficacy, or pharmacokinetics in humans. American Medical Wellness+2Holistic Medical Wellness+2
• Unknown long-term safety profile: Because long-term studies in animals (and especially in humans) remain limited or absent, potential chronic risks — such as abnormal cell growth, oncogenic risk (since c‑Met is associated with cell proliferation), off‑target effects, metabolic disturbances, or unwanted neuroplastic changes — remain uncharacterized. Indeed, although early patent‑stage safety reports claimed no “apparent toxicity,” those statements are not the same as rigorous, long-term toxicology data. Wikipedia+2PubMed Central+2
• Regulatory status / not approved for human therapy: Dihexa remains an investigational compound. It is not approved by major regulatory agencies for treatment of any neurological or cognitive disorder. Use as a “nootropic,” “brain‑enhancer,” or “anti‑aging peptide” thus occurs outside regulatory oversight, raising legal, safety, and ethical issues. Evolution Integrative Medicine+1
• Quality control / variability concerns (if acquired outside research settings): As with many investigational peptides, if sourced from unregulated suppliers or “grey-market” vendors, the actual purity, identity, and stability of “Dihexa” preparations may be uncertain — risking contamination, incorrect dosing, degradation, or impurities. ChemicalBook+2American Medical Wellness+2
• Scientific reproducibility & overinterpretation risk: Most of the promising findings come from animal models or in vitro data. Translating those to human biology is fraught with uncertainty. There is no guarantee that beneficial effects seen in rodents (or cell culture) will replicate in humans — particularly given differences in metabolism, brain complexity, lifespan, and disease mechanisms.
• Ethical, medical, and regulatory challenges: Even if Dihexa were shown effective in humans, long-term safety, risk of neoplasia (given c‑Met’s role in cell proliferation), off-target effects, neuroplasticity dysregulation, immune responses would all need careful assessment.

Interpretation: Where Dihexa Stands Scientifically (As of Now)

Dihexa appears to be one of the more promising “neurotrophic‑mimetic” peptides developed to date — with compelling preclinical data suggesting neuroregeneration, enhanced synaptic connectivity, and cognitive improvement in models of dementia or cognitive decline. Its small size, BBB permeability, and HGF‑mimetic mechanism make it structurally and functionally attractive as a research compound.

However, the evidence remains preclinical. Without controlled human trials (on pharmacokinetics, safety, efficacy, dosing, long-term effects), Dihexa cannot — at present — be considered a safe or approved treatment. Use outside controlled research settings would be experimental at best, and potentially risky.

Thus, from a scientific and medical standpoint, Dihexa remains a research compound — interesting, promising, but not ready for therapeutic or recreational use in humans.

For these reasons, any interest in Dihexa should be limited to strictly regulated research settings.

Frequently Asked Questions (FAQ) about Dihexa

1. What is Dihexa and what is its CAS number?
   • Dihexa is a synthetic oligopeptide (N‑hexanoic‑Tyr‑Ile‑(6)‑aminohexanoic amide), also known as PNB‑0408. Its CAS number is 1401708‑83‑5. Wikipedia+1
2. How does Dihexa work?
   • Dihexa binds to and potentiates the activity of hepatocyte growth factor (HGF) at the c‑Met receptor. This activation promotes synaptogenesis and spinogenesis in neurons — effectively mimicking neurotrophic effects, which may lead to enhanced neuroplasticity, neuronal survival, and improved cognitive functioning. PubMed Central+2Wikipedia+2
3. Has Dihexa been studied in humans?
   • As of now, there is no robust peer‑reviewed published data demonstrating safety or efficacy of Dihexa in humans. All publicly available reports are from animal or cell-based studies. American Medical Wellness+2Holistic Medical Wellness+2
4. What benefits have been observed (in preclinical studies)?
   • Enhanced synapse formation and dendritic spine growth; improved memory and learning in aged or cognitively impaired rodents; reversal of some cognitive deficits in Alzheimer’s‑model mice; neuroprotection and possibly reduced neuroinflammation; improved neuronal survival — collectively suggesting neuroregenerative and procognitive potential. PubMed Central+3Genetic Engineering & Biotechnology News+3PubMed Central+3
5. Can Dihexa cross the blood–brain barrier (BBB)?
   • Yes — one of the important features of Dihexa is its reported ability to cross the BBB, making it potentially effective in targeting CNS (brain) processes. ChemicalBook+2Genetic Engineering & Biotechnology News+2
6. What are the main risks or unknowns associated with Dihexa?
   • Unknown long-term safety (no human data), potential for abnormal neuronal growth or oncogenic risk (since c‑Met is associated with proliferation), possible off-target effects or toxicity, unpredictable effects on neuroplasticity, and risks associated with unregulated peptide sourcing (purity, contamination). Wikipedia+2PubMed Central+2
7. Is Dihexa approved by regulatory agencies (e.g. FDA) for treatment or cognitive enhancement?
   • No — Dihexa remains an investigational compound. It has not been approved for treatment of neurodegenerative diseases, cognitive decline, or any other human therapeutic indication. Evolution Integrative Medicine+1
8. Has Dihexa been proposed for use in any diseases (e.g. Alzheimer’s, Parkinson’s)?
   • Yes — preclinical research has explored Dihexa for neurodegenerative diseases, cognitive impairment, and even Parkinson‑like disease models (as a small‑molecule HGF mimetic). The rationale is its neurotrophic and neuroregenerative potential. Michael J. Fox Foundation+2Evolution Integrative Medicine+2
9. Given the current state of evidence — is Dihexa “safe” for nootropic or anti‑aging use?
   • From a scientific standpoint: No. Because of the lack of human data, uncharacterized long-term safety, regulatory unapproval, and uncertain quality of non‑research‑grade preparations, Dihexa should not be considered “safe” for nootropic, anti‑aging, or cognitive‑enhancement use outside research.
10. What would be required for Dihexa to become a safe, accepted therapeutic agent?
    • Rigorous preclinical toxicology studies, followed by carefully designed phased clinical trials in humans (dose‑finding, pharmacokinetics, safety, efficacy, long-term follow‑up), regulatory review, quality control standards, and post‑approval surveillance to monitor long-term effects, off-target risks, and safety in diverse populations.

Key Limitations in Current Knowledge

• The bulk of data is preclinical — animal or cell-based — which cannot reliably predict human outcomes.
• Long-term safety, toxicity, and possible side-effects — especially with chronic use — are unknown.
• Potential oncogenic risk: because Dihexa activates HGF/c‑Met, pathways associated with cell growth and proliferation, there is theoretical risk of abnormal cell growth or tumorigenesis; this has not been ruled out in long-term studies.
• Regulatory and legal status: Dihexa is not approved; non‑regulated use carries both legal and health risks.
• Variability and quality control issues if sourced outside strictly regulated research-grade production — risk of contamination, incorrect dosage, stability issues.
• Risk of overinterpretation: claims of “miracle neuro‑regeneration” or “anti‑aging brain therapy” are speculative until human data are available.

Conclusion (As of Current Evidence)

Dihexa is a small, blood–brain barrier permeable oligopeptide with potent neurotrophic and synaptogenic activity in preclinical models. The preclinical evidence suggests it could — in principle — support neuroregeneration, improve cognitive function, and treat or mitigate neurodegenerative conditions.

However, because human data are lacking, safety is unproven, and regulatory approval is absent, Dihexa remains a research compound — not a validated therapy or supplement. The promise is real, but so is the uncertainty and risk.

Accordingly, it is scientifically prudent to treat Dihexa as an interesting experimental molecule — one deserving of further study — but not as a safe or proven therapy.

For these reasons, any interest in Dihexa should be confined to controlled research settings, not personal use.

Disclaimer: This document is provided for research and educational purposes only. Dihexa is not approved for clinical, therapeutic, anti‑aging, or cognitive-enhancement use. Use outside regulated research settings may pose significant health risks.